Phase 2 Clinical Trial of Infusing Haploidentical K562-mb15-41BBL-Activated and Expanded Natural Killer Cells as Consolidation Therapy for Pediatric Acute Myeloblastic Leukemia

CONCLUSION: This study emphasizes the difficulties in recruiting patients for cell therapy trials, though NKAE cell infusion is safe and feasible. However, we cannot draw any conclusions regarding efficacy because of the small number of included patients and insufficient biological markers.PMID:33610500 | DOI:10.1016/j.clml.2021.01.013

Source: Clinical Lymphoma and Myeloma - February 21, 2021 Category: Cancer & Oncology Authors: Lara Maria G ómez García Adela Escudero Carmen Mestre Jose L Fuster Soler Antonia Pascual Mart ínez Jose M Vagace Valero Mar ía Vela Beatriz Ruz Alfonso Navarro Lucia Fern ández Adri án Fernández Alejandra Leivas Joaquin Mart ínez-López Cristina Source Type: research